A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study is currently recruiting participants.
Verified February 2013 by Theravance, Inc.
Sponsor:
Theravance, Inc.
Information provided by (Responsible Party):
Theravance, Inc.
ClinicalTrials.gov Identifier:
NCT01458340
First received: October 20, 2011
Last updated: February 27, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
| Condition | Intervention | Phase |
|---|---|---|
|
Attention-Deficit/Hyperactivity Disorder ADHD |
Drug: TD-9855 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
Resource links provided by NLM:
Further study details as provided by Theravance, Inc.:
Primary Outcome Measures:
- Adult ADHD Investigator Symptom Rating Scale (AISRS) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]The Adult ADHD Investigator Symptom Rating Scale (AISRS) is a modified version of the ADHD Rating Scale that more accurately reflects the impact and severity of ADHD among adults. It is a clinician-administered scale that measures all 18 symptoms of adult ADHD using a Likert scale (from 0 [not present] to 3 [severe]). The total ranges from 0 to 54.
Secondary Outcome Measures:
- Barkley Deficits in Executive Functioning Scale-short form: self report (BDEFS-SF:Self-Report) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]The Barkley Deficits in Executive Functioning Scale-short form: self report (BDEFS-SF:Self-Report) is an empirically based tool for evaluating dimensions of adult executive functioning in daily life. The BDEFS-SF offers an ecologically valid snapshot of the capacities involved in time management; organization and problem solving; self restraint; self motivation; and self-regulation of emotions. The total score on the BDEFS-SF range from 0 to 80.
| Estimated Enrollment: | 285 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Dose 1 |
Drug: TD-9855
Once daily
|
| Experimental: Placebo |
Drug: Placebo
Once daily
|
| Experimental: Dose 2 |
Drug: TD-9855
Once daily
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects must meet the following ADHD diagnostic and inclusion criteria:
- Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for current ADHD subtypes (ADHD combined type, ADHD predominately inattentive type, ADHD predominately hyperactive-impulsive type) as assessed by the clinical interview and confirmed by Adult Attention-Deficit/Hyperactivity Disorder Clinical Diagnostic Scale (ACDS V1.2).
- Subjects must have a total score of 24 or greater on the AISRS at both the Screening and Baseline Visits AND the Baseline Visit AISRS scores must not vary by more than 20% from Screening.
- Subjects are required to have CGI-S score ≥4 (moderate) at both the Screening and Baseline Visits. Subjects should have at least moderate severity for ADHD symptoms.
- For women of childbearing potential, documentation of a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 0. All female subjects of childbearing potential must be using a highly effective method of birth control during the study and for at least 1 month after completion of study drug dosing.
- A highly effective method of birth control is defined as one that results in a low failure rate (i.e., <1% per year) when used consistently and correctly, such as condom + diaphragm, condom + spermicide, diaphragm + spermicide, or intrauterine device [IUD] with documented failure rate of <1% per year, or oral/injectable/implanted hormonal contraceptives used in combination with a barrier method.
- Women are considered to be not of childbearing potential if they have had a total hysterectomy or bilateral tubal ligation (documentation for either must be provided before enrollment) or are at least 2 years postmenopausal. Female subjects cannot be breast-feeding.
Exclusion Criteria:
Any current psychiatric disorder other than ADHD as defined in DSM-IV-TR as assessed by Mini International Neuropsychiatric Interview (MINI). Subjects with dysthymia that does not require pharmacological treatment will not be excluded.
- MADRS total score >15.
- A diagnosis of ADHD NOS.
- Any diagnosis of lifetime bipolar disorder or psychotic disorder
- A current diagnosis of any severe comorbid Axis II disorder
- Any history of mental retardation, organic mental disorders due to general medical condition or pervasive developmental disorder as defined by DSM-IV-TR.-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01458340
Contacts
| Contact: Claudia Fuentes | 650-808-6000 | Cfuentes@theravance.com |
Locations
| United States, Florida | |
| Florida Clinical Research Center, LLC | Recruiting |
| Bradenton, Florida, United States, 34201 | |
| Contact: Jamie Smith 941-747-7900 jsmith@flcrc.com | |
| Principal Investigator: Andrew Cutler, M.D. | |
| Florida Clinical Research Center | Recruiting |
| Maitland, Florida, United States, 34201 | |
| Contact: Traci Howard thoward@flcrc.com | |
| Principal Investigator: Eduard Gfeller, M.D. | |
| Janus Ctr. for Psychiatric Research | Recruiting |
| Palm Beach, Florida, United States, 33407 | |
| Contact: Robert Chaney 561-238-3030 bchaney@januspsychresearch.com | |
| Principal Investigator: Janice Miller, MD | |
| United States, Georgia | |
| Carman Research | Recruiting |
| Smyrna, Georgia, United States, 30080 | |
| Contact: Brittany Childs 770-333-0093 brittany@carmanresearch.com | |
| Principal Investigator: Nathan Shapira, MD | |
| United States, Missouri | |
| Midwest Research Group | Recruiting |
| St. Charles, Missouri, United States, 63304 | |
| Contact: Michael Varisella 636-946-8032 info@midwestresearchgroup.com | |
| Principal Investigator: Richard Anderson, MD | |
| United States, Nevada | |
| Ctr. for Psychiatry & Behavioral Med. | Recruiting |
| Los Vegas, Nevada, United States, 89128 | |
| Contact: Ann Childress, MD 702-838-0742 drann87@aol.com | |
| Principal Investigator: Ann Childress, MD | |
| United States, New York | |
| Adult ADHD Program | Recruiting |
| New York, New York, United States, 10016 | |
| Contact: David Shaw 212-686-7500 | |
| Principal Investigator: Leonard Adler, MD | |
| United States, Oklahoma | |
| IPS Research | Recruiting |
| Oklahoma City, Oklahoma, United States, 73103 | |
| Contact: Kevin Short 405-235-8188 kshort@ipsresearch.com | |
| Principal Investigator: Louise Thurman, MD | |
| United States, Rhode Island | |
| Lincoln Research | Recruiting |
| Lincoln, Rhode Island, United States, 02865 | |
| Contact: Rosemary Whalen 401-305-5200 rw@lincolnresearch.org | |
| Principal Investigator: James Whalen, MD | |
| United States, Texas | |
| FutureSearch Clinical Trials | Recruiting |
| Austin, Texas, United States, 78731 | |
| Contact: Donald Garcia, MD 512-415-2401 donaldg@fstrials.com | |
| Principal Investigator: Donald Garcia, MD | |
| United States, Washington | |
| Summit Research Network (Seattle), LLC | Recruiting |
| Seattle, Washington, United States, 98104 | |
| Contact: Recruitment Team 206-292-2273 Washington@summitnetwork.com | |
| Principal Investigator: Supriya Kang, MD | |
Sponsors and Collaborators
Theravance, Inc.
More Information
No publications provided
| Responsible Party: | Theravance, Inc. |
| ClinicalTrials.gov Identifier: | NCT01458340 History of Changes |
| Other Study ID Numbers: | 0085 |
| Study First Received: | October 20, 2011 |
| Last Updated: | February 27, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Theravance, Inc.:
|
Adult ADHD Attention-Deficit/Hyperactivity Disorder |
Additional relevant MeSH terms:
|
Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Mental Disorders Diagnosed in Childhood Mental Disorders |
Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013